Clinical trial
A Phase II, Open Label, Multicenter Study of Single-Agent AT-101 in Patients With Relapsed or Refractory B-Cell Malignancies (Follicular Lymphoma, Mantle Cell Lymphoma, Diffuse Large Cell Lymphoma, or Small Lymphocytic Lymphoma/Chronic Lymphocytic Leukemia)
NCT00275431 is registered in ClinicalTrials.gov with Ascenta Therapeutics as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase II, Open Label, Multicenter Study of Single-Agent AT-101 in Patients With Relapsed or Refractory B-Cell Malignancies (Follicular Lymphoma, Mantle Cell Lymphoma, Diffuse Large Cell Lymphoma, or Small Lymphocytic Lymphoma/Chronic Lymphocytic Leukemia)
- Lead sponsor
- Ascenta Therapeutics
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- November 30, 2005
- Completion date
- December 31, 2008
- Enrollment
- 50 (actual)
- Sites
- 11
Conditions
As the registry lists them; a condition with its own page is linked.
chronic lymphocytic leukemia, diffuse large cell lymphoma, follicular lymphoma, mantle cell lymphoma, small lymphocytic lymphoma